Supplementary Fig. 2. Example adverse event (AE) management profiles for 12 patients treated with sorafenib during the DECISION study. Line graphs indicate the severity over time of AEs that led to dose modifications or permanent discontinuation. Colored bars in each panel indicate sorafenib dosing over time, in mg. Hand–foot skin reaction (HFSR) was sometimes reported by investigators as hand–foot syndrome (HFS)